Print | Email Page

Celgene successfully blocks PTAB institution of IPR involving REVLIMID®

March 2019

Jones Day represented Celgene Corporation in successfully blocking institution of inter partes review ("IPR") of a patent covering the use of Celgene's REVLIMID® brand drug to treat multiple myeloma. Alvogen Pine Book LLC ("Alvogen") filed a petition seeking review of U.S. Patent No. 7,968,569, which is directed to methods of treating multiple myeloma with REVLIMID®. Following Celgene's filing of its Patent Owner Preliminary Response to Alvogen's petition, the Patent Trial and Appeal Board ("PTAB") denied institution of inter partes review on March 14, 2019, finding that Alvogen had not shown a reasonable likelihood of prevailing in its unpatentability challenges because it failed to establish that the claimed methods would have been obvious at the time of the invention.

Alvogen Pine Brook, LLC, et al. v. Celgene Corporation, IPR No. 2018-01714 (PTAB)

For additional information about this matter, please contact: Anthony M. Insogna, Matthew J. Hertko, Cary Miller Ph.D.

Client(s): Celgene Corporation